NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Unconfirmed

**Date and time:** Tuesday 8 March 2022

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Richard Nicholas (Topic 1 Chair) Present for all items
2. Professor Stephen O’Brien (Topic 2 Chair) Present for all items
3. Dr Alex Cale Items 1 to 4.2.2
4. Michael Chambers Present for all items
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Present for all items
8. John Hampson Present for all items
9. Dr Nigel Langford Present for all items
10. Dr Andrea Manca Present for all items
11. Iain McGowan Present for all items
12. Dr Mudasar Mushtaq Items 1 to 4.2.2
13. Ugochi Nwulu Present for all items
14. Stella O’Brien Present for all items
15. Professor Subhash Pokhrel Present for all items
16. Professor Andrew Renehan Present for all items
17. Professor Matthew Stevenson Present for all items
18. Professor Paul Tappenden Present for all items

NICE staff present

Ross Dent, Associate Director Present for all items

Louise Jafferally, Project Manager Present for all items

Charlie Hewitt, Heath Technology Assessment Adviser Items 1 to 4.2.2

Alexander Filby, Heath Technology Assessment Adviser Items 5 to 5.2.2

Kirsty Pitt, Heath Technology Assessment Analyst Items 1 to 4.2.2

Catherine Parker, Heath Technology Assessment Analyst Items 5 to 5.2.2

Benjamin Gregory, Business Analyst, RIA Present for all items

Hayley Garnett, Senior Medical Editor Items 1 to 4.2.2

Ruth Melville, Senior Medical Editor Items 5 to 5.2.2

Emily Eaton Turner, Technical Analyst, Commercial Risk Assessment, Present for all items

Neha Jiandani, Technical Analyst, Commercial Liaison Present for all Items

Stephen Norton, Technical Analyst, Managed Access Items 1 to 4.2.2

Thomas Palmer, Health Technology Assessment Analyst, Interventional Procedures,

Items 1 to 4.2.2

Ella Fitzpatrick, Public Involvement Adviser, PIP Items 1 to 4.1.3 & 5 to 5.1.3

Mandy Tonkinson, Public Involvement Adviser, PIP Items 1 to 4.1.2 & 5 to 5.1.3

Georgina Fletcher, Media Relations Executive Items 1 to 4.2.2

Lyn Davis, Coordinator, MIP Items 1 to 4.1.3 & 5 to 5.1.3

Gemma Smith, Coordinator, COT Present for all items

Iain Cannell, Administrator, TA Present for all items

Mohammed Towhasir, Administrator, TA Items 1 to 4.2.2

External assessment group representatives present

Dan Gallacher, Warwick Evidence Items 1 to 4.1.3

Mandy Maredza, Warwick Evidence Items 1 to 4.1.3

Nigel Armstrong, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Sabine Grimm, Kleijnen Systematic Reviews Ltd (KSR) Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Adrian Bloor, Consultant Haematologist, clinical expert nominated by UK CLL Forum, Items 1 to 4.1.3

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, items 1 to 4.2.2

Professor Peter Hillmen, Professor of Experimental Haematology, clinical expert nominated by AbbVie, Items 1 to 4.1.3

Nick York, Patient expert nominated by Leukaemia Care, Items 1 to 4.1.3

Professor Gary McVeigh, Innovative Medicines Fund Clinical lead, NHS England, Items 5 to 5.2.2

Professor Riyaz Patel, Professor of Cardiology and Consultant Cardiologist, Clinical expert nominated by Cochrane Heart Group, Items 5 to 5.1.3

Dr Peter Penson, Reader in Cardiovascular Pharmacology, Patient expert nominated by HEART UK – The Cholesterol Charity, Items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Richard Nicholas welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted committee member apologies.

### News and announcements

* 1. None

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 11 January 2022.

### Appraisal of venetoclax for treating chronic lymphocytic leukaemia - CDF review of TA487 - [ID3886]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from AbbVie.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Committee member Michael Chambers declared financial Interests as he has been participating on an advisory panel for Pfizer, manufacturer of a possible comparator therapy, but in an unrelated disease area (prostate cancer). It was agreed his declaration would not prevent Michael from participating in discussions on this appraisal.
* Committee member Dr Richard Nicholas declared financial Interests as he has carried out advisory boards for Roche, manufacturer of a possible comparator therapy, but in an unrelated area (multiple sclerosis). It was agreed his declaration would not prevent Dr Nicholas from participating in discussions on this appraisal.
* Nominated clinical expert Professor Adrian Bloor declared financial interests as he has received consultancy, speaker, advisory board fees and conference funding from AbbVie, Janssen, Gilead, Novartis, and Roche. It was agreed his declaration would not prevent Professor Bloor from providing expert advice to the committee.
* Nominated clinical expert Professor Peter Hillmen declared financial interests as he has received honoraria for lecturing and advisory boards from Abbvie, Janssen, Pharmacyclics, Astra Zeneca, Beigene and Roche. His Institution, the University of Leeds, has received research support from Abbvie, Janssen, Pharmacyclics, Gilead and Roche. He also chairs IWCLL which has received support from Abbvie, Janssen, Pharmacyclics, Astra Zeneca, Beigene and Roche. It was agreed his declaration would not prevent Professor Hillmen from providing expert advice to the committee.
* Nominated patient expert Nick York declared non-financial professional and personal interests as he is a patient advocate for Leukaemia Care and indirect financial interests as Leukaemia Care has received unconditional funding grants from most companies which are comparators and AbbVie. It was agreed his declaration would not prevent Nick from providing expert advice to the committee.
* No further interests were declared for this appraisal.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Alex Cale, Iain McGowan, and Ugochi Nwulu.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10890>

### Appraisal of icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides [ID3831]

* 1. Part 1 – Open session
     1. The chair Professor Stephen O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Amarin Pharma.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Nominated clinical expert Professor Riyaz Patel declared the following interests.
* He has received honoraria and education grants from other companies not related to this product but involved with lipid management, including Amgen, Sanofi, Novartis, and Bayer.
* He has a small private practice dealing with patients with general cardiology issues.
* Leads a strategic effort in CVD prevention locally in East London and chair the NL ODN group to enhance CVD prevention in primary care.
* Is a committee member for Pan London groups on CVD prevention and familial hypercholesterolaemia.
* His institution (Barts Health) has joint working agreements with industry. But not with the manufacturer of this agent.
* He has recently been appointed topic advisor for the upcoming NICE update on CVD prevention and Lipids.
* His private practice includes general cardiology and lipid disorders.
* He is the clinical lead for CVD prevention at Barts Health and oversee the lipid service. It was agreed that his declarations would not prevent Professor Patel from providing expert advice to committee.
* Nominated patient expert Dr Peter Penson declared financial interests as he has received honoraria and/or travel reimbursement for events sponsored by AKCEA, Amgen, AMRYT, Link Medical, Mylan, Napp, and Sanofi. He holds shares in AstraZeneca which he inherited. HEART UK has received funding from Daiichi Sankyo, Amgen, and Novartis. It was agreed that his declarations would not prevent Dr Penson from providing expert advice to committee.
* No further interests were declared for this appraisal.
  + 1. The chair led a discussion of the consultation comments presented to the committee.
  1. Part 2– Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10736>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Wednesday 6 April 2022 and will start promptly at 09.30.